Stock AnalizCG Oncology, Inc. CGON
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026
CG Oncology, Inc. (CGON) is a healthcare company listed in the US with a market value of about $6.6B. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$237M, a net margin of -3851.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -16%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $6M | $4M | $1M | $204000 |
| Net income | -$237M | -$161M | -$88M | -$49M |
| Free cash flow | -$189M | -$132M | -$79M | — |
| EPS (diluted) | $-2.76 | $-2.08 | $-1.41 | $-15.65 |
| Net margin | -3851.1% | -3985.0% | -7729.5% | -23827.0% |
| ROIC | — | -19.8% | -12.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $91.46, 23% above the current price; targets range from $80.00 to $112.00; the consensus rating is “Strong buy”; expected EPS is $-2.96 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does CG Oncology pay a dividend?
Not currently.
Is CG Oncology a good stock to buy?
We do not give buy or sell advice. CG Oncology scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.